Abstract：
UNASSIGNED: Thrombotic thrombocytopenic purpura (TTP) is an ultra-rare blood disorder, characterized by severe ADAMTS13 deficiency. Affected individuals present with potentially life-threatening acute events and may experience sub-acute and chronic TTP manifestations often resulting in long-term organ damage. Incremental symptom prevalence before, during, and after an acute event as well as healthcare resource utilization (HCRU) and costs during and after an acute event were compared between people with TTP and matched non-TTP controls.
UNASSIGNED: This retrospective, matched study used data from Merative MarketScan Commercial Database and Medicare Supplemental Database (from January 1, 2008, through September 30, 2021) to identify people with TTP (inpatient diagnosis for \"thrombotic microangiopathy (TMA)\" or \"congenital TTP,\" and ≥1 claim for plasma exchange or infusion). People with TTP were matched (1:2) with non-TTP controls on age, sex, geographic region, index year, and select Elixhauser comorbidities.
UNASSIGNED: 255 people with TTP were matched with 510 non-TTP controls. Both cohorts had a mean age of 43.9 years; 71% were female. Overall, more people with TTP reported symptoms compared with non-TTP controls prior to (51% vs 43%), during (99% vs 52%), and after an acute event (85% vs 50%; p < 0.05 for all periods). Symptom prevalence decreased following an acute event compared with during an acute event, but remained high-85% of people with TTP experienced symptoms compared with 50% of non-TTP controls. HCRU and mean costs per patient per month were significantly higher in all care settings among people with TTP compared with non-TTP controls (p < 0.05).
UNASSIGNED: Identification of patient populations may have been limited due to coding errors, as the data were obtained from an administrative claims database.
UNASSIGNED: TTP is associated with a substantial symptom burden and increased costs and HCRU during and up to almost a year after acute events, demonstrating the longitudinal burden of this disease.
UNASSIGNED: This retrospective, matched study used data from Merative MarketScan Commercial Database and Medicare Supplemental Database (from January 1, 2008, through September 30, 2021) to identify people with TTP (inpatient diagnosis for \"thrombotic microangiopathy (TMA)\" or \"congenital TTP,\" and ≥1 claim for plasma exchange or infusion). People with TTP were matched (1:2) with non-TTP controls on age, sex, geographic region, index year, and select Elixhauser comorbidities.
UNASSIGNED: 255 people with TTP were matched with 510 non-TTP controls. Both cohorts had a mean age of 43.9 years; 71% were female. Overall, more people with TTP reported symptoms compared with non-TTP controls prior to (51% vs 43%), during (99% vs 52%), and after an acute event (85% vs 50%; p < 0.05 for all periods). Symptom prevalence decreased following an acute event compared with during an acute event, but remained high-85% of people with TTP experienced symptoms compared with 50% of non-TTP controls. HCRU and mean costs per patient per month were significantly higher in all care settings among people with TTP compared with non-TTP controls (p < 0.05).
UNASSIGNED: Identification of patient populations may have been limited due to coding errors, as the data were obtained from an administrative claims database.
UNASSIGNED: TTP is associated with a substantial symptom burden and increased costs and HCRU during and up to almost a year after acute events, demonstrating the longitudinal burden of this disease.
摘要：
■血栓性血小板减少性紫癜（TTP）是一种非常罕见的血液病，以严重的ADAMTS13缺乏为特征。受影响的个体存在潜在危及生命的急性事件，并可能经历亚急性和慢性TTP表现，通常导致长期器官损伤。之前症状患病率递增，during,在急性事件发生后以及急性事件期间和之后的医疗资源利用(HCRU)和费用在TTP患者和匹配的非TTP对照组之间进行比较.
■这次回顾展，配对研究使用Merative™MarketScan®商业数据库和Medicare补充数据库（从2008年1月1日至2021年9月30日）的数据来识别患有TTP（住院诊断为“血栓性微血管病（TMA）”或“先天性TTP，\"和≥1要求进行血浆置换或输注)。TTP患者的年龄与非TTP对照组相匹配（1：2），性别,地理区域,指数年，并选择Elixhauser合并症。
■255名TTP患者与510名非TTP对照者相匹配。两个队列的平均年龄为43.9岁；71％为女性。总的来说,与之前的非TTP对照相比，更多的TTP患者报告症状（51％vs43％），期间(99%vs52%)，和急性事件后（85％vs50％；所有时期p<0.05）。与急性事件期间相比，急性事件后症状患病率下降，但与50%的非TTP对照组相比,85%的TTP患者出现症状仍然很高.与非TTP对照组相比，所有TTP患者的HCRU和每个患者每月的平均费用均显着较高（p<0.05）。
■由于编码错误，患者人群的识别可能受到限制，因为数据是从行政索赔数据库中获得的。
■TTP与严重的症状负担和增加的费用以及急性事件发生后将近一年的HCRU相关，证明了这种疾病的纵向负担。
■这次回顾展，配对研究使用Merative™MarketScan®商业数据库和Medicare补充数据库（从2008年1月1日至2021年9月30日）的数据来识别患有TTP（住院诊断为“血栓性微血管病（TMA）”或“先天性TTP，\"和≥1要求进行血浆置换或输注)。TTP患者的年龄与非TTP对照组相匹配（1：2），性别,地理区域,指数年，并选择Elixhauser合并症。
■255名TTP患者与510名非TTP对照者相匹配。两个队列的平均年龄为43.9岁；71％为女性。总的来说,与之前的非TTP对照相比，更多的TTP患者报告症状（51％vs43％），期间(99%vs52%)，和急性事件后（85％vs50％；所有时期p<0.05）。与急性事件期间相比，急性事件后症状患病率下降，但与50%的非TTP对照组相比,85%的TTP患者出现症状仍然很高.与非TTP对照组相比，所有TTP患者的HCRU和每个患者每月的平均费用均显着较高（p<0.05）。
■由于编码错误，患者人群的识别可能受到限制，因为数据是从行政索赔数据库中获得的。
■TTP与严重的症状负担和增加的费用以及急性事件发生后将近一年的HCRU相关，证明了这种疾病的纵向负担。
